Type of Deal: Strategic investment through equity and compulsory convertible debentures as part of acquisition terms
Stake/Capacity: Dr. Rajendra Gadikota acquired 20% stake in A1 Labs on a fully diluted basis through 89,94,500 equity shares and 2,41,05,500 Compulsory Convertible Debentures
Deal Value: Total consideration of ₹33.80 crore (₹9.18 crore for equity shares + ₹24.62 crore for Compulsory Convertible Debentures)
Financial Impact: A1 Labs received capital infusion of ₹33.80 crore. Post-allotment, ownership structure changed from 100% subsidiary to Apitoria holding 80% and Dr. Rajendra Gadikota holding 20%.
Timeline: Transaction completed and all formalities finalized on September 30, 2026
Strategic Rationale: This transaction fulfills the terms agreed under the definitive agreements entered into as part of Apitoria's acquisition of A1 Biochem group. The arrangement allows Dr. Gadikota, the former promoter, to maintain 20% ownership while Apitoria retains the option to acquire this stake in the future as per agreed terms.
Approval Status: Completed. The transaction received shareholder approval through a special resolution and was based on a fair valuation report from a Chartered Accountant.
Reference Regulation: SEBI Regulation 30 of Listing Obligations and Disclosure Requirements Regulations, 2015
Additional Details:
The transaction qualifies as a related party transaction since Dr. Rajendra Gadikota is a director of A1 Labs
The transaction was conducted at arm's length basis
Regulation 37A of LODR Regulations is not applicable as there is no sale/lease/disposal of undertaking
This disclosure is in continuation to previous letters dated July 23, 2026 and September 12, 2026
